Allergy Therapeutics plc
AGY.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | £378,932 | £309,819 | £176,650 | £67,473 |
| - Cash | £12,790 | £21,676 | £12,915 | £13,522 |
| + Debt | £60,089 | £45,970 | £30,988 | £9,850 |
| Enterprise Value | £426,231 | £334,113 | £194,723 | £63,801 |
| Revenue | £21,014 | £34,030 | £21,627 | £33,572 |
| % Growth | -38.2% | 57.3% | -35.6% | – |
| Gross Profit | £4,268 | £20,862 | £9,217 | £20,520 |
| % Margin | 20.3% | 61.3% | 42.6% | 61.1% |
| EBITDA | -£22,965 | -£6,464 | -£21,040 | -£9,700 |
| % Margin | -109.3% | -19% | -97.3% | -28.9% |
| Net Income | -£29,047 | -£11,085 | -£24,565 | -£15,651 |
| % Margin | -138.2% | -32.6% | -113.6% | -46.6% |
| EPS Diluted | -0.006 | -0.002 | -0.007 | -0.006 |
| % Growth | -165.2% | 64.6% | -12.1% | – |
| Operating Cash Flow | -£21,088 | -£7,629 | -£21,854 | -£10,774 |
| Capital Expenditures | -£1,740 | -£1,524 | -£1,536 | -£1,865 |
| Free Cash Flow | -£22,828 | -£9,153 | -£23,390 | -£12,639 |